Antibody Development Service
Because of the inaccuracy and low efficiencies of traditional treatment, such as surgery, chemotherapy, and radiotherapy, in recent years, RDC (Radionuclide Drug Conjugate), with targeted diagnosis and imaging, has been widely noticed and studied in recent years.
The targeting biomolecules in RDC could be antibodies, small molecules, and peptides, in which antibodies are most commonly used, also name RAC (Radionuclide Antibody Conjugate).
Rdcthera, adapting the advanced antibody discovery technology, is professional at antibody discovery, screening, and synthesis.
Tumor-Specific Antigen
Antibody can identify the specific overexpressed antigens on tumor cells. In immunotherapy, we can detect different antigenic components and use them to induce an anti-tumor immune response in the body for tumor diagnosis and treatment. There are five mechanisms for the production of tumor-specific antigens shown below.
- Expression products of mutated genes or oncogenes;
- Abnormally expressed cellular proteins;
- Tumor antigens expressed by oncogenic viruses;
- Tissue-specific differentiation antigens;
- Abnormal cellular proteins and their products due to glycosylation.
For example, HER2, a 185 kDa transmembrane protein, is overexpressed in types of cancers, including breast, ovarian, endometrial, gastric, pancreatic, and prostate cancers. The overexpressed HER2 is an important validated diagnostic marker and treatment target in breast cancer.
Fig.1 Comparison between normal HER2-positive breast cell and HER2-positive breast cancer cell. (Okarvi SM, et al., Molecules. 2019)
Discovered Antibody Applied for RDC
Antibodies can bind with a high degree of specificity to the antigen and are easily cleared due to their relatively small size. Antibody design is the most important step in RDC development, as it determines the target cells and the efficiency and accuracy of the targeting process of the RDC. Several tumor-specific antigens, discovered in different types of tumor cells, are conjugated in the RDC.
Our Service
- Antibody Discovery Service
In RDC development, antibodies and antibody fragments were commonly used in target recognition. Different types of antibodies have different advantages. The plasma half-life time and blood clearance of intact antibodies are relatively longer, while the use of intact antibodies is limited because of the poor penetration into solid tumors and cell uptake. Notably, this penetrates and uptake limitation can be overcome by antibody fragments. However, the ultra-small size of antibody fragments with great penetrating is restricted by the labeling with radioactive substances, as the pharmacokinetics of antibodies can be affected by chelators. Rdcthera provides all types of antibody discovery services according to your project.
You can order personalized antibody design and screening services according to a specific target or cancer type in your research. We use the standard procedure to conduct antibody screening and verification.
- ELISA
- Immuno-precipitation
- Immunohistochemistry
- Western blotting
- Immuno-fluorescence
- Antibody Conjugation Service
After the synthesis of antibodies, we can offer the antibody conjugation service for you. Rdcthera has decades of experience in conjugation service. The three most common covalent bonds in antibody-conjugates are shown below.
With our highly-specific antibodies, Rdcthera can offer the most appropriate conjugation strategy to support your RDC project, according to the antibody's characteristics and your specific demand.
Why Choose Us
With years of experience in RDC development, Rdcthera has accumulated significant knowledge in quick and high throughput antibody design, screening, and synthesis. We have professional equipment and scientists to promote your project.
Industrial Leadership
Cost Efficient
Highly Customizable
Premium Quality
We are honored to share our experience and help our customers with this most important targeting part through RDC development. Please contact us for more information.
Reference
- Okarvi SM, AlJammaz I. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas[J]. Molecules. 2019 Aug 29;24(17):3142.
For research use only. Not intended for any clinical use.
Related Service
